{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:21:02Z","timestamp":1784647262597,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170167"],"award-info":[{"award-number":["82170167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcyt.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T21:04:10Z","timestamp":1734383050000},"page":"295-299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A successful haploidentical transplantation without conditioning regimen for a relapsed\/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-7556","authenticated-orcid":false,"given":"Zigang","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanzhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-859X","authenticated-orcid":false,"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.jcyt.2024.10.005_bib0001","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.jcyt.2024.10.005_bib0002","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.jcyt.2024.10.005_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"The New England journal of medicine"},{"issue":"7","key":"10.1016\/j.jcyt.2024.10.005_bib0004","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Advances"},{"issue":"9","key":"10.1016\/j.jcyt.2024.10.005_bib0005","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jcyt.2024.10.005_bib0006","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2020.248187","article-title":"Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades","volume":"106","author":"Cooper","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jcyt.2024.10.005_bib0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.21633","article-title":"Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma","volume":"85","author":"Osman","year":"2010","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1016\/j.jcyt.2024.10.005_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2024.10.005_bib0009","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2024.10.005_bib0010","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2024.10.005_bib0011","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.10.005_bib0012","article-title":"Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.jcyt.2024.10.005_bib0013","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients","volume":"117","author":"Guo","year":"2011","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jcyt.2024.10.005_bib0014","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.jcyt.2024.10.005_bib0015","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/7445","article-title":"Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling","volume":"5","author":"Frank","year":"1999","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.jcyt.2024.10.005_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdp297","article-title":"The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy","volume":"21","author":"Gill","year":"2010","journal-title":"Annals of Oncology: official journal of the European Society for Medical Oncology"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:23:51Z","timestamp":1744446231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1465324924009010"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A successful haploidentical transplantation without conditioning regimen for a relapsed\/refractory multiple myeloma patient after chimeric antigen receptor T-cell therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}]}}